Vitamin D metabolite profiles in moderate renal insufficiency of childhood

1988 ◽  
Vol 2 (4) ◽  
pp. 453-459
Author(s):  
Arlene Taylor ◽  
Michael E. Norman
Circulation ◽  
2002 ◽  
Vol 105 (20) ◽  
pp. 2361-2366 ◽  
Author(s):  
James L. Januzzi ◽  
Steven M. Snapinn ◽  
Peter M. DiBattiste ◽  
Ik-Kyung Jang ◽  
Pierre Theroux

PEDIATRICS ◽  
1983 ◽  
Vol 71 (1) ◽  
pp. 56-58
Author(s):  
W. R. Griswold ◽  
V. Reznik ◽  
S. A. Mendoza ◽  
D. Trauner ◽  
A. C. Alfrey

A child with renal insufficiency was treated with the oral phosphate binder aluminum hydroxide from age 6 to 31 months. The prescribed dose of elemental aluminum varied from 31 to 108 mg/kg/d. Concurrently the patient developed vitamin D-resistant osteomalacia which failed to improve with parathyroidectomy. Encephalopathy with myoclonic seizures, loss of speech, and motor impairment also occurred. Serum and bone aluminum levels were elevated at 334 µg/L (normal 7 ± 3 µg/L) and 156 mg/kg (normal 3.3 ± 2.9 mg/kg), respectively. This case demonstrates that aluminum may accumulate in tissue of children receiving oral aluminum hydroxide. The accumulation of aluminum may have contributed to the vitamin D-resistant osteomalacia and the encephaiopathy in this patient. Children receiving aluminum-containing antacids as phosphate binders should be monitored for aluminum accumulation and signs of aluminum intoxication.


2006 ◽  
Vol 17 (4 suppl 2) ◽  
pp. S64-S68 ◽  
Author(s):  
Carmine Zoccali ◽  
Raffaele Maio ◽  
Giovanni Tripepi ◽  
Francesca Mallamaci ◽  
Francesco Perticone

Sign in / Sign up

Export Citation Format

Share Document